Nuveen
CADL icon

Nuveen’s Candel Therapeutics CADL Stock Holding History

Nuveen’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
142,978
+49,820
+53% +$376K ﹤0.01% 2740
2026
Q1 		$456K Buy
93,158
+676
+0.7% +$3.68K ﹤0.01% 2874
2025
Q4 		$523K Sell
92,482
-117,180
-56% -$630K ﹤0.01% 2853
2025
Q3 		$1.07M Buy
209,662
+117,180
+127% +$677K ﹤0.01% 2594
2025
Q2 		$468K Buy
92,482
+14,337
+18% +$73.8K ﹤0.01% 2906
2025
Q1 		$442K Buy
78,145
+9,919
+15% +$81K ﹤0.01% 2945
2024
Q4 		$592K Buy
68,226
+2,009
+3% +$11.9K ﹤0.01% 2926
2024
Q3 		$459K Sell
66,217
-315,971
-83% -$1.96M ﹤0.01% 3045
2024
Q2 		$2.37M Buy
+382,188
New +$2.87M ﹤0.01% 2299

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen's CADL Position: Q2 2026 in Review

Nuveen increased its Candel Therapeutics (CADL) stake by 53% in Q2 2026, buying an estimated $376K and bringing the position to 142,978 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

Nuveen first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.37M in Q2 2024. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Nuveen held 142,978 shares of Candel Therapeutics worth $1.47M as of Q2 2026.
  • Nuveen bought 49,820 Candel Therapeutics shares in Q2 2026, an estimated $376K.
  • Candel Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2740 holding.
  • Nuveen first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Nuveen's Candel Therapeutics position peaked at $2.37M in Q2 2024.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.